Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

News / Press Releases

: Press Releases

Press Releases

Tonix Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for TNX-102 SL for Treatment of Agitation in Alzheimer’s Disease

July 16, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Presented New Data Related to Suicidal Ideation and Behaviors in Military-Related PTSD from the Phase 2 AtEase Study at the American Society of Clinical Psychopharmacology

May 31, 2018 • 4:30 PM EDT

Tonix Pharmaceuticals to Present at the 2018 BIO International Convention

May 30, 2018 • 8:00 AM EDT

Tonix Pharmaceuticals Reports Preliminary Results from a Phase 1 Pivotal Multiple-Dose Bridging Pharmacokinetic (PK) Study of Tonmya® or TNX-102 SL

May 24, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the 2018 American Society of Clinical Psychopharmacology

May 23, 2018 • 4:05 PM EDT

Tonix Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs Update

May 14, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the BIO KOREA 2018 International Convention

May 7, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Receives IND Clearance by U.S. FDA for TNX-102 SL in Agitation in Alzheimer’s Disease

May 1, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York

April 4, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD

April 3, 2018 • 7:00 AM EDT

« Previous
1
2
3
4
5
6
7
8
9
10
...29
Next »

Show All

News / Press Releases : Press Releases